Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca    AZN   GB0009895292

My previous session
Most popular
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets

AstraZeneca : 3Q Operating Profit Rises Despite Product Sales Decline

share with twitter share with LinkedIn share with facebook
share via e-mail
11/09/2017 | 08:55am CEST

By Adam Clark

AstraZeneca PLC (AZN.LN) reported Thursday that its operating profit for the third quarter of 2017 increased, boosted by a one-off tax benefit, but product sales continued to decline due to the loss of exclusivity on some key drugs.

The pharmaceutical company's operating profit rose 12% to $1.15 billion, up 9% in constant currencies. Pretax profit rose 33% to $1.82 billion.

However, product sales for the quarter fell 3% to $4.88 billion, which AstraZeneca said was due to a loss of exclusivity on its Crestor and Seroquel products. Total revenue rose 9% to $6.23 billion, benefiting from a contribution from externalization revenue--proceeds from partnerships and licensing deals.

AstraZeneca narrowed its 2017 guidance, saying it now expects its core earnings per share to be towards the favorable end of a low to mid-teens percentage decline. It reiterated its 2017 revenue guidance of a low to mid single-digit percentage drop.

Chief Executive Pascal Soriot said the most notable developments of the quarter were positive data from the company's drugs pipeline, especially its Tagrisso and Imfinzi cancer therapy candidates.

Write to Adam Clark at adam.clark@dowjones.com; @AdamDowJones

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ASTRAZENECA
10/17Novo Nordisk appoints Ludovic Helfgott executive vice president Biopharm
10/17ASTRAZENECA : to continue UK investment freeze due to Brexit uncertainty
10/17Beset by copies, Roche gets sales boost from China
10/16ASTRAZENECA : Halts UK Investment
10/16Novo Nordisk appoints Ludovic Helfgott executive vice president Biopharm
10/16ASTRAZENECA : building a new open innovation pharma company
10/16MERCK AND : US FDA grants Lynparza Orphan Drug Designation for pancreatic cancer..
10/16FDA Gives Orphan Drug Status to AstraZeneca, Merck & Co.'s Lynparza
10/16ASTRAZENECA : US FDA grants Lynparza Orphan Drug Designation for pancreatic canc..
10/16ASTRAZENECA : FDA Orphan Drug for Lynparza in pancreatic cancer
More news
News from SeekingAlpha
10/17Johnson & Johnson suspends clinical development of antiviral lumicitabine 
10/16AstraZeneca's Lynparza an Orphan Drug in U.S. for pancreatic cancer 
10/15FDA issues new guidance aimed at more efficient drug development 
10/15AstraZeneca halts UK investments over Brexit uncertainties - Reuters 
10/15Healthcare 16-24% Target Net Gains Pace WallStars For October 
Financials ($)
Sales 2018 22 368 M
EBIT 2018 5 472 M
Net income 2018 2 276 M
Debt 2018 14 734 M
Yield 2018 3,59%
P/E ratio 2018 41,45
P/E ratio 2019 34,89
EV / Sales 2018 4,84x
EV / Sales 2019 4,57x
Capitalization 93 630 M
Duration : Period :
AstraZeneca Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 78,4 $
Spread / Average Target 3,1%
EPS Revisions
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Sean Bohen Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA9.72%93 630
JOHNSON & JOHNSON-4.19%359 141
PFIZER20.87%256 643
NOVARTIS0.07%212 170
ROCHE HOLDING LTD.-4.56%204 777
MERCK AND COMPANY23.44%185 661